Free Submission Public Relations &
Deutsch English


EntreMed, Inc. - Product Pipeline Review - 2013: New research report available at Fast Market Research

Print article Print article
2013-06-13 11:12:11 - New Pharmaceuticals market report from Global Markets Direct: "EntreMed, Inc. - Product Pipeline Review - 2013"

Global Market Direct's pharmaceuticals report, "EntreMed, Inc. - Product Pipeline Review - 2013" provides data on the EntreMed, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, EntreMed, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from EntreMed, Inc. and industry-specific third party sources, put together by Global Markets Direct's team.


* EntreMed, Inc. - Brief EntreMed, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
* Review of current pipeline of EntreMed, Inc. human therapeutic division.
* Overview of

pipeline therapeutics across various therapy areas.
* Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
* Product profiles for late stage and clinical stage products of EntreMed, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
* Recent updates of the EntreMed, Inc.'s pipeline in the last quarter.
* Key discontinued and dormant projects.
* Latest news and deals relating to the products.

Full Report Details at
- ..

Reasons to Get this Report

* Evaluate EntreMed, Inc.'s strategic position with total access to detailed information on its product pipeline.
* Assess the growth potential of EntreMed, Inc. in its therapy areas of focus.
* Identify new drug targets and therapeutic classes in the EntreMed, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
* Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
* Exploit collaboration and partnership opportunities with EntreMed, Inc..
* Avoid Intellectual Property Rights related issues.
* Explore the dormant and discontinued projects of EntreMed, Inc. and identify potential opportunities in those areas.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
EntreMed, Inc. Snapshot
EntreMed, Inc. Overview
Key Information
Key Facts
EntreMed, Inc. - Research and Development Overview
Key Therapeutic Areas
EntreMed, Inc. - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Combination Treatment Modalities
EntreMed, Inc. - Pipeline Products Glance
EntreMed, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
EntreMed, Inc. - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
EntreMed, Inc. - Drug Profiles
Product Description
Mechanism of Action
R&D Progress
Product Description
Mechanism of Action
R&D Progress
Product Description
Mechanism of Action
R&D Progress
Product Description
Mechanism of Action
R&D Progress
MKC-1 + [pemetrexed disodium]
Product Description
Mechanism of Action
R&D Progress
EntreMed, Inc. - Pipeline Products By Target
EntreMed, Inc. - Pipeline Products by Route of Administration
EntreMed, Inc. - Pipeline Products By Mechanism of Action
EntreMed, Inc. - Recent Pipeline Updates
EntreMed, Inc. - Dormant Projects
EntreMed, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
2-methoxyestradiol Nanocrystal Colloidal Dispersion + [sunitinib malate]
2-Methoxyestradiol Nanocrystal Colloidal Dispersion + [temozolomide]
EntreMed, Inc. - Company Statement
EntreMed, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
EntreMed, Inc., Recent Developments
EntreMed, Inc.- Press Release
Jan 23, 2013: EntreMed Initiates Phase II Trial In Advanced/Metastatic Soft Tissue Sarcoma
Jan 07, 2013: EntreMed Files New Drug Clinical Trial Application For ENMD-2076 With China SFDA To Advance Global Development Strategy
Jan 04, 2013: EntreMed Announces Initiation Of Second Site For Phase II Trial In Triple-negative Breast Cancer
Nov 09, 2010: EntreMed To Present ENMD-2076 Phase I Data In Hematological Studies At ASH Annual Meeting
Jul 13, 2010: EntreMed's ENMD-2076 Demonstrates Significant Anti-Cancer Activity In Multiple Myeloma Preclinical Models
Jun 02, 2010: EntreMed's ENMD-2076 Demonstrates Preclinical Antitumor Activity In Colorectal Cancer
May 11, 2010: EntreMed Initiates Second Site In ENMD-2076 Phase II Ovarian Cancer Study
Apr 16, 2010: EntreMed Raises Additional $3 Million To Further Support Clinical Development Of ENMD-2076 In Ovarian Cancer
Apr 13, 2010: EntreMed Begins Phase II Study For ENMD-2076 In Ovarian Cancer
Feb 16, 2010: EntreMed Receives Orphan Drug Designation For ENMD-2076 In Leukemia
Financial Deals Landscape
EntreMed, Inc., Deals Summary
EntreMed, Inc., Pharmaceuticals & Healthcare, Deal Details
EntreMed Enters Into Agreement With UTEK
EntreMed Enters Into Agreement With University of New South Wales And Children's Cancer Institute
Licensing Agreements
Selected Value Therapeutics Exercises Its Option Licensing Agreement With EntreMed For ENMD-2076
Equity Offering

Full Table of Contents is available at:

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Bill Thompson
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News


Terms & Conditions | Privacy | About us | Contact